ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV) is a biopharmaceutical company focused on the discovery and development of targeted antiviral therapies with two candidates in mid-to-late stage clinical development. ContraVir’s lead candidate, FV-100, is an orally available nucleoside analogue prodrug that is being developed for the treatment of herpes zoster, or shingles, which is currently in phase 3 clinical development. ContraVir is also developing CMX157, a highly potent analog of the successful antiviral drug tenofovir DF (Viread), for the Hepatitis B virus (“HBV”) in phase 2 clinical studies. For more information, visit the company’s website at www.contravir.com